| Name | Epsilon-V1-2 |
| Description | Epsilon-V1-2 has been extensively investigated for its function as a PKC epsilon (PKCε) inhibitor. Epsilon-V1-2 has been widely applied in studies addressing ovarian aging, apoptosis in human granulosa cells, cerebral ischemia-reperfusion injury, brain development, hepatocyte insulin signaling, and neuronal cell death under ischemic conditions. Epsilon-V1-2 has been shown to effectively reduce PKCε activity, thereby enabling detailed exploration of regulatory pathways involving mitochondrial dynamics, calcium overload, AKT activation, brain atrophy, insulin resistance, and ferroptosis. Epsilon-V1-2 demonstrates notable therapeutic relevance in models of stroke, SHORT syndrome, hepatic steatosis, and brain injury, supporting its continued evaluation as a potential pharmacological agent across multiple disease contexts. |
| In vitro | Epsilon-V1-2 (1 μM, 24 hours) significantly inhibits OA-induced Cx43 Ser368 phosphorylation and protects myocardial gap junctions from OA-induced disruption [2]. |
| In vivo | Epsilon-V1-2 (20 mg/kg/day, subcutaneously implanted with 0.1 mL osmotic pump, administered daily for 4 weeks) significantly improved the beating score of transplanted FVB mouse hearts in C57BL/6J mice [3]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100.00 mg/mL (118.49 mM), Sonication is recommended.
H2O : ≥ 80 mg/mL, Sonication is recommended.
|
| Keywords | Epsilon-V1-2 | Epsilon-V-1-2 | EpsilonV12 | Epsilon V1 2 |
| Inhibitors Related | PKN1/2-IN-1 | Forskolin | Darovasertib | Ellagic acid | α-Vitamin E | Ro-3306 | Staurosporine | Methyl-Hesperidin | Gondoic acid | Miltefosine | Fasudil hydrochloride | R59949 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Peptide Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library |
United States
